LFST
LifeStance Health Group, Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $51.1M | Q1 2026 | — |
|
|
|||
| Center Margin | $135.9M | Q1 2026 | — |
|
|
|||
| Clinician base | 8,349 | Q1 2026 | — |
|
|
|||
| First quarter visit volumes | 2.5M | Q1 2026 | — |
| Free Cash Flow non-GAAP | $22.3M | Q1 2026 | — |
|
|
|||
| adjusted EBITDA margin non-GAAP | 12.7% | Q1 FY2026 call | — |
| center margin as percentage of revenue | 33.7% | Q1 FY2026 call | — |
| centers | 575 | Q1 FY2026 call | — |
| clinician base growth | 11% | Q1 FY2026 call | — |
| clinicians added | 309 | Q1 FY2026 call | — |
| gross leverage | 1.6 | Q1 FY2026 call | — |
| net leverage | 0.5 | Q1 FY2026 call | — |
| total clinician base | 8,349 | Q1 FY2026 call | — |
| total revenue per visit | $163 | Q1 FY2026 call | — |
| visit volumes | 2.5M | Q1 FY2026 call | — |
|
|
|||
| visits per average clinician growth | 7% | Q1 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LFST
this stock
LifeStance Health Group, Inc.
|
$4.26B | +56.1% | +13.9% | — | 2.1% |
|
HCA
HCA Healthcare, Inc.
|
$94.07B | -10.5% | +7.1% | 14.6 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.14B | -12.8% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$17.76B | +3.8% | -2.3% | 10.7 | 4.7% |
|
DVA
Davita Inc.
|
$15.13B | +107.5% | +6.5% | 22.0 | 7.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LFST | +6.9% | +43.9% | +48.5% | +2.6% | +56.1% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +3.9% | +44.6% | +40.3% | +2.0% | +45.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.